- Home
- NAUT vs RCS Comparison
NAUT vs RCS Comparison
Compare NAUT & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- RCS
- Stock Information
- Founded
- NAUT 2016
- RCS 1994
- Country
- NAUT United States
- RCS United States
- Employees
- NAUT N/A
- RCS N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- RCS Investment Managers
- Sector
- NAUT Industrials
- RCS Finance
- Exchange
- NAUT Nasdaq
- RCS Nasdaq
- Market Cap
- NAUT 104.7M
- RCS 358.4M
- IPO Year
- NAUT N/A
- RCS N/A
- Fundamental
- Price
- NAUT $1.43
- RCS $7.07
- Analyst Decision
- NAUT Strong Sell
- RCS
- Analyst Count
- NAUT 1
- RCS 0
- Target Price
- NAUT $1.75
- RCS N/A
- AVG Volume (30 Days)
- NAUT 513.3K
- RCS 141.1K
- Earning Date
- NAUT 10-28-2025
- RCS 01-01-0001
- Dividend Yield
- NAUT N/A
- RCS 10.12%
- EPS Growth
- NAUT N/A
- RCS N/A
- EPS
- NAUT N/A
- RCS N/A
- Revenue
- NAUT N/A
- RCS N/A
- Revenue This Year
- NAUT N/A
- RCS N/A
- Revenue Next Year
- NAUT N/A
- RCS N/A
- P/E Ratio
- NAUT N/A
- RCS N/A
- Revenue Growth
- NAUT N/A
- RCS N/A
- 52 Week Low
- NAUT $0.62
- RCS $4.51
- 52 Week High
- NAUT $2.95
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- NAUT 76.98
- RCS 33.20
- Support Level
- NAUT $0.95
- RCS $7.53
- Resistance Level
- NAUT $1.24
- RCS $7.41
- Average True Range (ATR)
- NAUT 0.12
- RCS 0.22
- MACD
- NAUT 0.04
- RCS -0.09
- Stochastic Oscillator
- NAUT 72.00
- RCS 6.63
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.